[go: up one dir, main page]

LV13630B - Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone - Google Patents

Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone Download PDF

Info

Publication number
LV13630B
LV13630B LVP-06-45A LV060045A LV13630B LV 13630 B LV13630 B LV 13630B LV 060045 A LV060045 A LV 060045A LV 13630 B LV13630 B LV 13630B
Authority
LV
Latvia
Prior art keywords
pyrrolidinone
phenyl
compound
carbamoylmethyl
phenotropil
Prior art date
Application number
LVP-06-45A
Other languages
English (en)
Inventor
Grigorijs Veinbergs
Maksims Vorona
Maija Dambrova
Liga Zvejniece
Ligita Karina
Ivars Kalvins
Aleksandrs Cernobrovijs
Original Assignee
Olainfarm As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olainfarm As filed Critical Olainfarm As
Priority to LVP-06-45A priority Critical patent/LV13630B/en
Priority to EA200801978A priority patent/EA014668B1/ru
Priority to SI200730253T priority patent/SI2013166T1/sl
Priority to UAA200812099A priority patent/UA96440C2/ru
Priority to CA2647206A priority patent/CA2647206C/en
Priority to AT07726915T priority patent/ATE460396T1/de
Priority to DE602007005244T priority patent/DE602007005244D1/de
Priority to EEP200800063A priority patent/EE05536B1/xx
Priority to ES07726915T priority patent/ES2342024T3/es
Priority to DK07726915.7T priority patent/DK2013166T3/da
Priority to EP07726915A priority patent/EP2013166B1/en
Priority to PT07726915T priority patent/PT2013166E/pt
Priority to PCT/EP2007/052424 priority patent/WO2007104780A2/en
Priority to GEAP200710934A priority patent/GEP20104915B/en
Priority to MEP-2009-293A priority patent/ME01192B/me
Priority to HRP20090524AA priority patent/HRP20090524C1/hr
Priority to CNA2007800177832A priority patent/CN101448786A/zh
Priority to US12/226,332 priority patent/US9102615B2/en
Priority to PL07726915T priority patent/PL2013166T3/pl
Publication of LV13630B publication Critical patent/LV13630B/en
Priority to LT2008075A priority patent/LT5589B/lt
Priority to CY20101100506T priority patent/CY1110170T1/el
Priority to US14/688,633 priority patent/US9382203B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Claims (7)

  1. LV 13630 IZGUDROJUMA FORMULA 1. N-Karbamoilmetil-4(7?j-fenil-2-pirolidinons (I) ar neirotropo aktivitāti: Ph«^ NL CONH 2, (I) kur * apzīmē hiralo oglekļa atomu.
  2. 2. Savienojuma (I) pēc p. 1lietošana depresiju ārstēšanai.
  3. 3. Savienojuma (I) pēc p. 1., lietošana stresa izraisītu saslimšanu ārstēšanai. 10
  4. 4. Savienojuma (I) pēc p. 1., lietošana lokomotorās aktivitātes regulācijai.
  5. 5. Savienojuma (I) pēc p. 1., lietošana miorelaksācijai.
  6. 6. Savienojuma (I) pēc p. 1., lietošana analgēzijai.
  7. 7. Savienojuma (I) pēc p. 1. iegūšanas paņēmiens, kas atšķiras ar to, ka 4(i?)-fenil-2-pirolidinona N-alkilēšanu veic ar brometiķskābes etilesteri stipras bāzes klātienē un iegūtā N-alkoksikarbonilmetil-4(i?)-fenil-2-pirolidinona karbamoilēšanai lieto amonjaku. 15
LVP-06-45A 2006-03-16 2006-03-16 Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone LV13630B (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
LVP-06-45A LV13630B (en) 2006-03-16 2006-03-16 Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
PCT/EP2007/052424 WO2007104780A2 (en) 2006-03-16 2007-03-15 N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use
PT07726915T PT2013166E (pt) 2006-03-16 2007-03-15 N-carbamoilmetilo-4(r)fenilo-2-pirrolidinona, processos de sua preparação e utilização farmacêutica
UAA200812099A UA96440C2 (ru) 2006-03-16 2007-03-15 Способ получения и применения фармакологически активного n-карбамоилметил-4-(r)-фенил-2-пирролидинона
CA2647206A CA2647206C (en) 2006-03-16 2007-03-15 N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use
AT07726915T ATE460396T1 (de) 2006-03-16 2007-03-15 N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinon, verfahren zu dessen herstellung und pharmazeutische verwendung
DE602007005244T DE602007005244D1 (de) 2006-03-16 2007-03-15 N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinon, verfahren zu dessen herstellung und pharmazeutische verwendung
EEP200800063A EE05536B1 (et) 2006-03-16 2007-03-15 N-karbamoüülmetüül-4-(R)-fenüül-2-pürrolidinoon, selle valmistamise meetod ja farmatseutiline kasutamine
ES07726915T ES2342024T3 (es) 2006-03-16 2007-03-15 N-carbamoilmetil-4(r)-fenil-2-pirrolidinona, su procedimiento de prepaacion y uso farmaceutico.
DK07726915.7T DK2013166T3 (da) 2006-03-16 2007-03-15 N-carbamoylmethyl-4(R)-phenyl-2-pyrrolidon, fremgangsmåde til fremstilling heraf og farmaceutisk anvendelse
GEAP200710934A GEP20104915B (en) 2006-03-16 2007-03-15 N-carbamoylmethyl-4-(r) – phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use
EA200801978A EA014668B1 (ru) 2006-03-16 2007-03-15 Способ получения и применения фармакологически активного n-карбамоилметил-4(r)-фенил-2-пирролидинона
SI200730253T SI2013166T1 (sl) 2006-03-16 2007-03-15 N-karbamoilmetil-4(r)-fenil-2-pirolidinon, postopek za njegovo pripravo in farmacevtska uporaba
EP07726915A EP2013166B1 (en) 2006-03-16 2007-03-15 N-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use
MEP-2009-293A ME01192B (me) 2006-03-16 2007-03-15 Metod pripreme i upotreba farmakološki aktivnog n-karbamoilmetil-4(r)-fenil-2-pirolidinona
HRP20090524AA HRP20090524C1 (hr) 2006-03-16 2007-03-15 Metoda priprave i upotreba farmakološki aktivnog n-karbamoilmetil-4(r)-fenil-2-pirolidinona
CNA2007800177832A CN101448786A (zh) 2006-03-16 2007-03-15 N-氨基甲酰甲基-4(r)-苯基-2-吡咯烷酮的制备方法及药物用途
US12/226,332 US9102615B2 (en) 2006-03-16 2007-03-15 N-Carbamoylmethy1-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use
PL07726915T PL2013166T3 (pl) 2006-03-16 2007-03-15 N-karbamoilometylo-4(R)-fenylo-2-pirolidynon, sposób jego wytwarzania i zastosowanie farmaceutyczne
LT2008075A LT5589B (lt) 2006-03-16 2008-09-22 N-karbamoilmetil-4-(r)-fenil-2-pirolidinonas, jo gavimo būdas ir farmacinis panaudojimas
CY20101100506T CY1110170T1 (el) 2006-03-16 2010-06-08 Ν-καρβαμοϋλμεθυλ-4(-r)-φαινυλ-2-πυρρολιδινονη, μεθοδος παρασκευης της και φαρμακευτικη χρηση αυτης
US14/688,633 US9382203B2 (en) 2006-03-16 2015-04-16 N-carbamoylmethyl-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-06-45A LV13630B (en) 2006-03-16 2006-03-16 Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone

Publications (1)

Publication Number Publication Date
LV13630B true LV13630B (en) 2007-12-20

Family

ID=38461010

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-06-45A LV13630B (en) 2006-03-16 2006-03-16 Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone

Country Status (21)

Country Link
US (2) US9102615B2 (lv)
EP (1) EP2013166B1 (lv)
CN (1) CN101448786A (lv)
AT (1) ATE460396T1 (lv)
CA (1) CA2647206C (lv)
CY (1) CY1110170T1 (lv)
DE (1) DE602007005244D1 (lv)
DK (1) DK2013166T3 (lv)
EA (1) EA014668B1 (lv)
EE (1) EE05536B1 (lv)
ES (1) ES2342024T3 (lv)
GE (1) GEP20104915B (lv)
HR (1) HRP20090524C1 (lv)
LT (1) LT5589B (lv)
LV (1) LV13630B (lv)
ME (1) ME01192B (lv)
PL (1) PL2013166T3 (lv)
PT (1) PT2013166E (lv)
SI (1) SI2013166T1 (lv)
UA (1) UA96440C2 (lv)
WO (1) WO2007104780A2 (lv)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2392915C1 (ru) * 2009-04-14 2010-06-27 Федеральное государственное учреждение "Новокузнецкий научно-практический центр медико-социальной экспертизы и реабилитации инвалидов Федерального агентства по здравоохранению и социальному развитию" (ФГУ ННПЦ МСЭ и РИ Росздрава) Способ формирования двигательных функций у инвалидов с позвоночно-спинно-мозговой травмой

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV14346B (lv) * 2009-11-05 2011-07-20 Grindeks, A/S 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
RU2437659C1 (ru) * 2010-11-12 2011-12-27 Государственное образовательное учреждение высшего профессионального образования "Российский государственный педагогический университет им. А.И. Герцена" (РГПУ им. А.И. Герцена) Средство, обладающее антидепрессивным, анксиолитическим и ноотропным действием
WO2012123358A1 (en) 2011-03-11 2012-09-20 Grindeks 4r,5r-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity
RU2480214C1 (ru) 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
JP6285419B2 (ja) 2012-05-08 2018-02-28 ニコックス アフサァルミィクス、 インコーポレイテッドＮｉｃｏｘ Ｏｐｈｔｈａｌｍｉｃｓ， Ｉｎｃ． 疎水性治療剤の調製物、製造方法およびその使用
TW201408294A (zh) 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療帕金森氏症之用除
TW201408293A (zh) 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
LV15003B (lv) * 2013-10-22 2015-08-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
LV15015B (lv) 2013-12-13 2015-12-20 Olainfarm, A/S 3-karboksi-4-(R)-fenilpirolidin-2-ona sāls un tā pielietošana
LV15016B (lv) 2013-12-18 2016-01-20 Olainfarm, A/S N-karbamoilmetil-4(R)-fenil-2-pirolidinona polimorfās formas
EP2891491A1 (en) 2014-01-03 2015-07-08 Merz Pharma GmbH & Co. KGaA Use of (r)-phenylpiracetam for the treatment of sleep disorders
LV15072B (lv) 2014-05-14 2016-09-20 Olainfarm, A/S Farmaceitiska kompozīcija izmantošanai patoloģiska stāvokļa, kam raksturīga paaugstināta iNOS gēna ekspresija, profilaksei un ārstēšanai
EP3127539A1 (en) * 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
EP4582412A1 (en) * 2022-08-31 2025-07-09 Korea University Research and Business Foundation Chiral gamma lactam derivative or pharmaceutically acceptable salt thereof, and preparation method therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
RU2289404C1 (ru) * 2005-04-06 2006-12-20 ГОУ ВПО "Московский государственный медико-стоматологический университет Министерства здравоохранения РФ" Способ премедикации у пациентов со средним уровнем психоэмоционального напряжения при амбулаторных стоматологических вмешательствах

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2392915C1 (ru) * 2009-04-14 2010-06-27 Федеральное государственное учреждение "Новокузнецкий научно-практический центр медико-социальной экспертизы и реабилитации инвалидов Федерального агентства по здравоохранению и социальному развитию" (ФГУ ННПЦ МСЭ и РИ Росздрава) Способ формирования двигательных функций у инвалидов с позвоночно-спинно-мозговой травмой

Also Published As

Publication number Publication date
LT5589B (lt) 2009-08-25
CA2647206A1 (en) 2007-09-20
EE200800063A (et) 2008-12-15
PT2013166E (pt) 2010-06-09
ES2342024T3 (es) 2010-06-30
HRP20090524C1 (hr) 2017-03-10
SI2013166T1 (sl) 2010-07-30
DE602007005244D1 (de) 2010-04-22
UA96440C2 (ru) 2011-11-10
EP2013166B1 (en) 2010-03-10
WO2007104780A3 (en) 2007-11-29
EE05536B1 (et) 2012-04-16
US9102615B2 (en) 2015-08-11
CN101448786A (zh) 2009-06-03
US20100022784A1 (en) 2010-01-28
EP2013166A2 (en) 2009-01-14
DK2013166T3 (da) 2010-07-05
US20150216846A1 (en) 2015-08-06
US9382203B2 (en) 2016-07-05
CY1110170T1 (el) 2015-01-14
HRPK20090524B3 (hr) 2012-12-31
HRP20090524A2 (hr) 2009-12-31
EA200801978A1 (ru) 2009-04-28
LT2008075A (en) 2009-06-25
ME01192B (me) 2012-12-20
ATE460396T1 (de) 2010-03-15
GEP20104915B (en) 2010-03-10
CA2647206C (en) 2011-09-27
WO2007104780A2 (en) 2007-09-20
EA014668B1 (ru) 2010-12-30
PL2013166T3 (pl) 2010-08-31

Similar Documents

Publication Publication Date Title
CA2647206C (en) N-carbamoylmethyl-4-(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use
RU2140901C1 (ru) АНАЛОГИ γ-АМИНОМАСЛЯНОЙ КИСЛОТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
González-Sabı́n et al. CAL-B-catalyzed resolution of some pharmacologically interesting β–substituted isopropylamines
Baures et al. Crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-[(3-cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
US8957226B2 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
CA2702467A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
IL160045A (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacture of levetiracetam and analogues
ZA200501311B (en) Pyrrolidone derivatives as MAOB inhibitors
IL185545A (en) Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives and intermediate compounds
WO2023196614A1 (en) Methods and compounds for treating neurological disorders
ATE289583T1 (de) Stereoisomere von propyl-isopropylacetamid, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische zubereitungen
Wang et al. New synthesis of β-aryl-GABA drugs
Sabala et al. Asymmetric synthesis of α, β-substituted γ-amino acids via conjugate addition
HK1133005A (en) N- carbamoylmethyl- 4- (r) -phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use
WO2007104781A2 (en) Method for manufacturing of r-enantiomer of n-carbamoylmethyl-4-phenyl-2-pyrrolidone
Ai et al. Chiral N-phosphonyl imine chemistry: asymmetric additions of glycine enolate to diphenyl diamine-based phosphonyl imines
CA2780040C (en) 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity
JP2008508335A (ja) Ｍａｏｂインヒビターとしてのベンジルオキシ誘導体
RS20100352A2 (sr) Metod pripreme i upotreba farmakološki aktivnog n-karbamilmetil-4(r)-fenil-2-pirolidinona
Ol’shevskaya et al. Synthesis of carborane analogues of γ-aminobutanoic acid
CN116162128A (zh) 一种抗病毒感染的核苷衍生物及其制备方法与用途
KR100845366B1 (ko) 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
HK1084383B (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
HK1075885A1 (en) 20-Hydroxyeicosatetraenoic acid production inhibitors